According to a survey released on Monday, the market for respiratory syncytial virus (RSV) vaccines is predicted to reach $9 billion by 2029, an increase of over $8 billion from 2023.
The research was released in May following the FDA’s clearance of two RSV vaccines, Arexvy by GSK and Abrysvo by Pfizer. GlobalData is a prominent provider of data and analytics.
Moderna’s mRNA-1345 and AstraZeneca’s Beyfortus are also anticipated to establish a claim in the market before the upcoming RSV season in September.
The four medicines collectively “will account for 90% of total forecast sales in 2029 and are the key factors contributing to the significant growth in the global RSV market,” according to research. Jasper Morley, a GlobalData drug intelligence analyst, in a statement.
RSV is a typical infectious illness of the respiratory system and lungs that can lead to further health issues including bronchiolitis and pneumonia. Although infections in healthy infants and adults are less severe, some patient populations, including elderly patients or those with impaired immune systems, may develop life-threatening symptoms. RSV is responsible for up to 10,000 fatalities annually in the US.
According to the survey, Arexvy is expected to grow rapidly and take the lead in the market after receiving clearance from the US and EU in May and June, respectively.
Over a seven-year prediction, the vaccine is expected to maintain its top position, resulting in sales of more than a quarter of the whole global RSV market, or just over $2.5 billion, in 2029.
Abrysvo is currently seeking EU clearance despite getting US approval in May. Sales of $1.7 billion are anticipated, placing it third behind Moderna’s mRNA-1345.
An mRNA-based vaccination called mRNA-1345 is presently pending clearance in Australia and the EU for use in both children and adults.
The medication is anticipated to go on sale in 2024, exceed Abrysvo in sales, and reach $2.4 billion in 2029.
AstraZeneca Beyfortus is expected to generate $1.27 billion in worldwide sales after getting clearance from the EU late last year and the US on July 17. The recombinant monoclonal antibody is the first medication of its kind to be recommended for newborns throughout their first RSV season for illness prevention.
“The RSV market is primed to become a significant pharmaceutical battleground over the next seven years,” said Morley. “The leading four RSV medications are all indicated prophylactically and keen to establish themselves before the start of the autumn season.
The possibility of future medicine approvals, such as maternal and regional vaccines, would provide therapies a competitive edge and a favorable position in the market, the author continued. “Fierce competition is to be expected.”
